A detailed history of Pathstone Holdings, LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Pathstone Holdings, LLC holds 13,544 shares of NTLA stock, worth $163,611. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,544
Previous 13,550 0.04%
Holding current value
$163,611
Previous $303,000 8.25%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$19.72 - $27.36 $118 - $164
-6 Reduced 0.04%
13,544 $278,000
Q2 2024

Aug 14, 2024

BUY
$20.02 - $27.22 $14,954 - $20,333
747 Added 5.83%
13,550 $303,000
Q1 2024

May 13, 2024

BUY
$23.82 - $32.8 $129,437 - $178,235
5,434 Added 73.74%
12,803 $352,000
Q4 2023

Feb 14, 2024

BUY
$23.16 - $32.34 $170,666 - $238,313
7,369 New
7,369 $224,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $918M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Pathstone Holdings, LLC Portfolio

Follow Pathstone Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pathstone Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pathstone Holdings, LLC with notifications on news.